Simplify Logo

Full-Time

Machine Learning Engineer

Posted on 7/23/2024

Elegen

Elegen

51-200 employees

Custom DNA synthesis for biotech applications

Biotechnology
Healthcare

Compensation Overview

$140k - $180kAnnually

+ Bonus + Equity + Benefits

Mid

San Carlos, CA, USA

Category
Applied Machine Learning
AI & Machine Learning
Required Skills
Python
Data Science
Git
Data Structures & Algorithms
SQL
Requirements
  • B.S. with 3+ years of experience or M.S. in machine learning or data science.
  • Ability to collaborate and communicate effectively with bench science and software teams.
  • Proficiency in Python.
  • Knowledge of database architecture and querying (SQL).
  • Familiar with software development best practices, including version control using GitHub, testing, and tracking (Jira).
Responsibilities
  • Develop algorithms and machine learning models to advance Elegen’s novel synthetic DNA production platform.
  • Visualize data and evaluate predictions to inform collaborators about the impact of models on current and future products.
  • Identify model architectures, feature sets, hyperparameters, and metrics for optimal model performance.
  • Apply machine learning and feature engineering to identify potential improvements to Elegen’s processes and products.
  • Manage datasets for model training and feature investigation.
  • Collaborate with software teams to integrate machine learning models into commercial workflows.

Elegen focuses on improving the process of manufacturing synthetic DNA to meet the needs of the bioeconomy. The company provides custom DNA synthesis services to researchers, biotech companies, and pharmaceutical firms that require high-quality synthetic DNA for various applications, including biomanufacturing and mRNA-based treatments. Elegen's services are characterized by fast turnaround times and high accuracy, which are essential for clients' research and development. Unlike traditional DNA manufacturing methods, Elegen's approach reduces time and costs while enabling the production of valuable biologics and therapeutics. The company's goal is to support advancements in synthetic biology and biomanufacturing, particularly in the development of mRNA medicines and other advanced therapeutics.

Company Stage

Seed

Total Funding

$42.9M

Headquarters

San Carlos, California

Founded

2017

Growth & Insights
Headcount

6 month growth

14%

1 year growth

32%

2 year growth

114%
Simplify Jobs

Simplify's Take

What believers are saying

  • The recent $35M Series B funding, led by prominent investors like Triatomic Capital and GSK, will accelerate the expansion of Elegen’s ENFINIA™ DNA product line and enhance its clinical manufacturing capabilities.
  • Elegen's collaboration and licensing agreement with GSK to use their proprietary cell-free DNA manufacturing technology in developing vaccines and medicines highlights the company's potential for significant industry impact.
  • The commercial launch of the enhanced ENFINIA™ DNA, which offers highly complex DNA in as fast as 10 business days, positions Elegen as a leader in rapid and reliable DNA synthesis.

What critics are saying

  • The synthetic biology market is highly competitive, requiring Elegen to continuously innovate to maintain its edge.
  • Dependence on key partnerships, such as with GSK, could pose risks if these relationships were to change or dissolve.

What makes Elegen unique

  • Elegen's cell-free DNA manufacturing technology offers a significant advantage over traditional plasmid-based methods, reducing contamination risks and accelerating production timelines.
  • The company's ENFINIA™ DNA product line provides highly complex, NGS-verified DNA with rapid turnaround times, setting a new industry standard.
  • Elegen's Early Access Program fosters strong client relationships and provides an additional revenue stream by offering early access to their latest DNA breakthroughs.
INACTIVE